RET and non-small cell lung carcinoma: Vandetanib, lenvatinib, and cabozantinib, which are multitargeted kinase inhibitors, have demonstrated antitumour effect in RET-positive NSCLC in phase II trials with response rates ranging from 16% to 53% [104,105,106,107].